Last week, the Food and Drug Administration (FDA) announced it was revoking the “adequate provision” guidance for pharmaceutical advertising under which the health care industry has operated since 1997. To briefly explain: The FDA has long maintained a framework that pharma ads were permitted as long as they summarized the drug’s benefits and risks and then provided access to the full product labeling elsewhere. Now, the FDA is prompting companies – under an expanded set of criteria – to alter previously approved pharmaceutical ads to more accurately represent full benefit and risk profiles for the advertised products or pull down the ads. 

American Action Forum President Doug Holtz-Eakin recently broke down what benefit pharma ads provide to the health care industry, and it’s worth reading. But in the intervening days, the Office of Prescription Drug Promotion (OPDP), which is the office that is responsible for overseeing the drug advertisement portfolio at the FDA, publicly released untitled letters (yes, that is what they are called) listing the “infractions” that have inspired the FDA’s forthcoming crackdown on pharmaceutical advertising. These untitled letters are official reprimands by the FDA to companies that have violated some part of the advertising regulations governing pharma ads. 

OPDP has historically taken a light-touch enforcement posture to regulating these ads. In 2024, the office only released five untitled letters; before that, it issued only 27 since 2017. These letters focused primarily on the ads’ representations of efficacy, rather than any specific risks or side effects of the drug. Now, however, OPDP is orchestrating a highly visible crackdown on ads for failing to present “fair balance” (benefits versus risks), as well as for, in its historical assessment, making overstated efficacy claims. The sudden pivot from reasonable assessment of adherence to the spirit of the law to public-facing escalation, accompanied by press statements and headline–grabbing targets, looks less like routine compliance work and more like a political project cloaked in consumer protection.  

While we can agree that it is important for companies to obey the law and that reassessing regulations or guidance is not inherently bad, the blunt methods used to execute this regulatory blitz are troubling. First, it’s arbitrary and destabilizing. For years, sponsors have relied on well-worn rules and iterative FDA feedback to calibrate consumer-facing promotions. When enforcement whiplashes from subtle but fair enforcement to aggressive crackdown, without any precipitating change in the regulated industry, companies are left guessing which widely used creative conventions – such as happy music and bright colors – will suddenly be treated as misbranding. That uncertainty chills useful patient education and slows legitimate campaigns – especially for chronic diseases where awareness itself drives diagnosis and treatment adherence. There is ample research that shows ad exposure led to increases in treatment initiation and improved medication adherence. 

Second, if FDA’s crackdown is meant to correct the content of television ads, it simply makes no sense to punish the medium rather than the message. Social platforms and 30-second TV formats are inherently constrained, which limits the amount of content that can be included in that time frame. Mark Gardner, a lawyer who specializes in FDA law, suggested ads could become 10 minutes long, and this would be impractical. The regulatory answer should be clear, medium-specific guidance (e.g., scannable risk-info overlays, mandated landing pages with standardized risk summaries, and machine-readable labeling links), not sporadic gotcha letters after millions of compliant submissions have already been filed. OPDP’s own data show more than 70,000 submissions of proposed pharma advertising in 2024, covering roughly 150,000 individual promotional pieces. Snapping from minimal action to sweeping threats of maximal enforcement signals process failure, not sponsor malfeasance.  

Third, the crackdown risks harming patients by reducing the salience of legitimate risk information. If sponsors defensively stuff TV and social media ads with dense warnings to preempt enforcement, audiences tune out. Behavioral research (and FDA experience) suggests that useful risk communication requires hierarchy and design, not maximalism. A rules-of-the-road update would improve comprehension by both industry and patients; simply reaching for headlines under the guise of policing creates confusion for consumers. 

The FDA’s public messaging around the crackdown leans on a narrative that regulators had “gone soft” and must now restore order. Staging a campaign against high-visibility ads is textbook optics. It looks tough while sidestepping more difficult structural work, such as modernizing promotional rules for short-form video, influencer marketing, and AI-generated content. The selection of enforcement targets that guarantee headlines further blurs the line between risk-based oversight and symbolic politics.  

If FDA truly wants safer, more truthful direct-to-consumer pharma advertising, three fixes could outperform splashy crackdowns: 

• Modernize guidance for social and short-form media. Issue medium-specific standards (font size, dwell time, mandatory QR code to full prescribing information, structured risk tags) and safe harbors for compliant formats. 
• Prioritize pre-clearance pilots over public punishments. Expand voluntary advisory reviews for TV and digital creatives in sensitive categories (e.g., weight-loss, oncology) with rapid feedback cycles, reducing post-hoc disputes. 
• Target demonstrable harm rather than headlines. Focus on cases with evidence of patient confusion, off-label inducement, or safety signal distortion – not merely celebrity sizzle. 

Enforcement is essential. But swinging from constructive, realistic regulatory engagement to performative toughness undermines predictability, chills patient-facing education, and substitutes politics for policy. A durable solution requires clear, forward-looking standards that reflect how Americans consume information today – on phones, in feeds, and in seconds – not more letters that make news but don’t make the situation better.